SRX246 是一种强效、中枢神经系统穿透性、高选择性、口服生物可利用的血管加压素 1a (V1a) 受体拮抗剂 (对人的 V1a 的 Ki=0.3 nM)。SRX246 在 V1b 和 V2 受体上没有相互作用，在64个其他受体类，包括 35 个 G 蛋白不偶联受体上也显示出可忽略的结合。SRX246 正在开发用于治疗应激相关疾病的药物。
货号:ajcx15680
CAS:512784-93-9
分子式:C42H49N5O5
分子量：703.87
溶解度:Soluble in DMSO
纯度：98%
存储：Store at -20°C
库存：现货

Background:

SRX246 is a potent, CNS-penetrant, highly selective, orally bioavailable vasopressin 1a (V1a) receptor antagonist (Ki=0.3 nM for human V1a). SRX246 has no interaction at V1b and V2 receptors. SRX246 also displays negligible binding at 64 others receptors classes, including 35 G-proteincoupled receptors. SRX246 is under development for the treatment of stress-related disorders[1].

SRX246 (2 mg/kg; i.v.) treatment shows that the Cmax, AUC0-∞ and t1/2 values are 953 ng/mL, 1141 ng ?h/mL, and 6.02 hours, respectively, in plasma pharmacokinetics. Following an oral administration (dose 20 mg/kg), The Cmax, AUC0-∞ and t1/2 values are 98.4 ng/mL, 624 ng ?h/mL and 2.38 hours, respectively[1]. Animal Model: Male Sprague-Dawley rats[1]

[1]. Guillon CD, et al. Azetidinones as vasopressin V1a antagonists. Bioorg Med Chem. 2007 Mar 1;15(5):2054-80. [2]. Fabio KM, et al. Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. J Pharm Sci. 2013 Jun;102(6):2033-2043.